UY29840A1 - Compuestos de pirimidina amida como inhibidores de pgds - Google Patents
Compuestos de pirimidina amida como inhibidores de pgdsInfo
- Publication number
- UY29840A1 UY29840A1 UY29840A UY29840A UY29840A1 UY 29840 A1 UY29840 A1 UY 29840A1 UY 29840 A UY29840 A UY 29840A UY 29840 A UY29840 A UY 29840A UY 29840 A1 UY29840 A1 UY 29840A1
- Authority
- UY
- Uruguay
- Prior art keywords
- pirimidine
- compound
- pgds inhibitors
- amida
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 241000670727 Amida Species 0.000 title 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title 1
- 101710145576 Prostaglandin-H2 D-isomerase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72357005P | 2005-10-04 | 2005-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29840A1 true UY29840A1 (es) | 2007-05-31 |
Family
ID=37635758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29840A UY29840A1 (es) | 2005-10-04 | 2006-10-04 | Compuestos de pirimidina amida como inhibidores de pgds |
Country Status (27)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7759350B2 (en) * | 2005-09-15 | 2010-07-20 | Orchid Research Laboratories Ltd. | Pyrimidine carboxamides |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用 |
| ES2748599T3 (es) | 2007-08-27 | 2020-03-17 | Dart Neuroscience Cayman Ltd | Compuestos terapéuticos de isoxazol |
| US8779197B2 (en) | 2007-10-11 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| WO2009049181A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| CA2703220A1 (en) * | 2007-11-13 | 2009-05-22 | Pfizer Global Research And Development | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| ES2528129T3 (es) * | 2008-02-06 | 2015-02-04 | Msd K.K. | Derivado de sulfonil piperacina sustituido en la posición 3 |
| AU2009246446B2 (en) * | 2008-05-13 | 2014-06-26 | Cayman Chemical Company, Incorporated | Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase |
| CA2724998A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| JP2011524894A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| AP3272A (en) | 2008-09-22 | 2015-05-31 | Cayman Chem Co | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prosaglandin D2 mediated diseases |
| KR101367057B1 (ko) | 2009-03-17 | 2014-02-25 | (주)아모레퍼시픽 | 피부 자극 완화용 조성물 |
| WO2010056044A2 (ko) * | 2008-11-11 | 2010-05-20 | (주)아모레퍼시픽 | 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물 |
| KR101252335B1 (ko) | 2009-07-16 | 2013-04-08 | (주)아모레퍼시픽 | 피부 노화 방지용 조성물 |
| RU2496778C2 (ru) | 2009-03-09 | 2013-10-27 | Тайхо Фармасьютикал Ко., Лтд. | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу |
| PH12012501385A1 (en) | 2010-01-22 | 2014-10-22 | Taiho Pharmaceutical Co Ltd | Piperazine compound having a pgds inhibitory effect |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| US9199976B2 (en) | 2010-06-01 | 2015-12-01 | The University Of Queensland | Haematopoietic-prostaglandin D2 synthase inhibitors |
| CN106943407A (zh) * | 2010-07-26 | 2017-07-14 | 赛诺菲 | 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途 |
| TW201217335A (en) | 2010-09-07 | 2012-05-01 | Taiho Pharmaceutical Co Ltd | Prostaglandin d synthase inhibitory piperidine compounds |
| KR101271223B1 (ko) | 2011-01-27 | 2013-06-07 | 한국과학기술연구원 | 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제 |
| EP2800568A4 (en) * | 2012-01-06 | 2015-06-10 | Univ South Florida | COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR |
| ES2640049T3 (es) * | 2012-08-24 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Derivados de 3,6-dihidropirimidina 2,4,5,6-sustituidos como inhibidores de la polimerasa del virus de la hepatitis B (VHB) para el tratamiento de, por ejemplo, la hepatitis crónica |
| WO2017103851A1 (en) | 2015-12-17 | 2017-06-22 | Astex Therapeutics Limited | Quinoline-3-carboxamides as h-pgds inhibitors |
| US10669270B2 (en) * | 2016-03-14 | 2020-06-02 | Emory University | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| CA3066979A1 (en) | 2017-06-13 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as h-pgds inhibitors |
| US11357759B2 (en) | 2017-10-29 | 2022-06-14 | China Medical University | Composition including ADAM9 inhibitor and the use thereof |
| CN111479814A (zh) | 2017-12-13 | 2020-07-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的稠合的吡啶 |
| IL277455B2 (en) * | 2018-03-23 | 2024-05-01 | Step Pharma S A S | Aminopyrimidine derivatives as ctps1 inhibitors |
| BR112021008976A2 (pt) | 2018-11-08 | 2021-08-03 | Glaxosmithkline Intellectual Property Development Limited | compostos químicos |
| AU2021272972A1 (en) * | 2020-05-13 | 2022-12-08 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| WO2021256569A1 (ja) | 2020-06-19 | 2021-12-23 | 佐藤製薬株式会社 | Ｈ－ｐｇｄｓを阻害する縮環化合物 |
| US12331046B2 (en) * | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
| CN113004208A (zh) * | 2021-03-08 | 2021-06-22 | 沈阳药科大学 | 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用 |
| JP2024540477A (ja) * | 2021-11-17 | 2024-10-31 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | ハンチントン病を治療するためのｈｔｔモジュレータとしてのｎ－（２ｈ－インダゾール－５－イル）ピラジン－２－カルボキサミド誘導体及び類似化合物 |
| WO2023113023A1 (ja) | 2021-12-17 | 2023-06-22 | 佐藤製薬株式会社 | Ｈ－ｐｇｄｓを阻害するアザインドール誘導体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2934543A1 (de) * | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| JP2000226372A (ja) * | 1999-02-01 | 2000-08-15 | Nippon Soda Co Ltd | アミド化合物、その製造方法及び農園芸用殺虫剤 |
| AU7315700A (en) * | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| JP2003112985A (ja) | 2001-10-01 | 2003-04-18 | Nre Happiness Kk | 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット |
| JPWO2004011430A1 (ja) * | 2002-07-25 | 2005-11-24 | アステラス製薬株式会社 | ナトリウムチャネル阻害剤 |
| DE60329513D1 (de) * | 2002-07-30 | 2009-11-12 | Banyu Pharma Co Ltd | Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff |
| DE602004024375D1 (de) * | 2003-02-14 | 2010-01-14 | Glaxo Group Ltd | Carboxamidderivate |
| PT1471057E (pt) * | 2003-04-25 | 2006-05-31 | Actimis Pharmaceuticals Inc | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 |
| BRPI0415167A (pt) * | 2003-10-07 | 2006-11-28 | Renovis Inc | composto de amina como ligandos de canal de ìon e usos dos mesmos |
| AU2005209257A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
-
2006
- 2006-10-03 DO DO2006000210A patent/DOP2006000210A/es unknown
- 2006-10-03 AR ARP060104348A patent/AR056871A1/es unknown
- 2006-10-03 PE PE2010000532A patent/PE20110118A1/es not_active Application Discontinuation
- 2006-10-03 PE PE2006001202A patent/PE20070589A1/es not_active Application Discontinuation
- 2006-10-04 EP EP06816247.8A patent/EP1937652B1/en active Active
- 2006-10-04 NZ NZ567208A patent/NZ567208A/en not_active IP Right Cessation
- 2006-10-04 KR KR1020087008306A patent/KR101457966B1/ko not_active Expired - Fee Related
- 2006-10-04 ES ES06816247.8T patent/ES2514471T3/es active Active
- 2006-10-04 UA UAA200805322A patent/UA93213C2/ru unknown
- 2006-10-04 MY MYPI20080754 patent/MY151172A/en unknown
- 2006-10-04 RU RU2008117170/04A patent/RU2420519C2/ru not_active IP Right Cessation
- 2006-10-04 CA CA2624749A patent/CA2624749C/en not_active Expired - Fee Related
- 2006-10-04 SG SG201007241-1A patent/SG166121A1/en unknown
- 2006-10-04 JP JP2008534664A patent/JP5452925B2/ja active Active
- 2006-10-04 CN CN200910138053.9A patent/CN101538246B/zh active Active
- 2006-10-04 BR BRPI0616815-9A patent/BRPI0616815A2/pt not_active IP Right Cessation
- 2006-10-04 TW TW095136806A patent/TWI415839B/zh not_active IP Right Cessation
- 2006-10-04 CN CNA2006800365786A patent/CN101282943A/zh active Pending
- 2006-10-04 UY UY29840A patent/UY29840A1/es unknown
- 2006-10-04 AU AU2006299428A patent/AU2006299428B2/en not_active Ceased
- 2006-10-04 WO PCT/US2006/038841 patent/WO2007041634A1/en not_active Ceased
-
2008
- 2008-03-07 TN TNP2008000104A patent/TNSN08104A1/en unknown
- 2008-03-10 ZA ZA200802222A patent/ZA200802222B/xx unknown
- 2008-03-24 IL IL190411A patent/IL190411A/en not_active IP Right Cessation
- 2008-03-26 CR CR9832A patent/CR9832A/es not_active Application Discontinuation
- 2008-04-02 EC EC2008008335A patent/ECSP088335A/es unknown
- 2008-04-04 US US12/062,641 patent/US8202863B2/en active Active
- 2008-04-28 NO NO20082000A patent/NO20082000L/no not_active Application Discontinuation
- 2008-05-02 MA MA30891A patent/MA29925B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29840A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| SV2009002861A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| PA8774101A1 (es) | Compuesto de pirmidina | |
| ECSP14013173A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida | |
| HN2011000874A (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| BR0107934A (pt) | Carboxamidas de pirimidina úteis como inibidores de isozimas pde4 | |
| UY32938A (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
| NI201100081A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes. | |
| ECSP088765A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| UY31976A (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
| CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
| UY29506A1 (es) | Nuevas formas cristalinas de bromuro de tiotropio | |
| CL2011002461A1 (es) | Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica. | |
| CL2011002463A1 (es) | Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica. | |
| CL2008003495A1 (es) | Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras. | |
| NO20081483L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma | |
| DOP2010000239A (es) | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
| ECSP099328A (es) | Análogos de pirazol | |
| UY30988A1 (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds | |
| CL2012000885A1 (es) | Compuestos derivados de feniloxadiazol, inhibidores de las prostaglandinas sintasa (pgds); procedimiento de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica que comprende dichos compuestos, util para tratar un trastorno inflamatorio o alergico. | |
| AR062566A1 (es) | Compuestos de pirazolo (3,4-b]piridina, un procedimiento para su preparacion y composicion farmaceutica | |
| GT200500056A (es) | Compuestos utiles para el tratamiento de enfermedades | |
| CU20060180A7 (es) | Derivados de formamida para el tratamiento de enfermedades | |
| BRPI0509137A (pt) | compostos para o tratamento de doenças | |
| SV2006002059A (es) | Compuestos para el tratamiento de enfermedades ref. pc32232a |